ALK and non-small cell lung carcinoma: Since alectinib shows a better PFS and adverse event profile than crizotinib in Japanese patients with ALK-inhibitor-naïve ALK+ NSCLC [11], it has been approved for the treatment of recurrent or refractory ALK+ ALCL in Japan.